MDGL — Madrigal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $10.62bn
- $10.13bn
- $958.40m
Brief: Madrigal Expands Its Mash Pipeline With Exclusive Global Licensing Agreement For Six Preclinical Sirna Programs
Madrigal, China's Suzhou Ribo sign license deal for liver‑disease programs (updated)
Madrigal, Suzhou Ribo in license deal for liver‑disease programs
Brief: Suzhou Ribo Life Science Signs Exclusive Worldwide Licensing Deal With Madrigal
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule
Biotech Inventiva's 50% surge shows investor optimism over liver disease drug
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Brief: Madrigal Pharmaceuticals Announces Grant Of Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
U.S. RESEARCH ROUNDUP-Datadog, IBM, Netflix
U.S. RESEARCH ROUNDUP- American Express Co, Ameriprise Financial, Mastercard
Brief: Madrigal Expands Its Mash Pipeline With Exclusive Global License Agreement For Ervogastat
U.S. RESEARCH ROUNDUP-Carmax, Cintas, Nike
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Agios Pharmaceuticals, Dycom Industries, Lowe's Companies
Madrigal Pharma Q3 revenue rises on Rezdiffra demand
Brief: Madrigal Pharmaceuticals Q3 EPS USD -5.08
Brief: Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-BlackRock, EQT, Ovintiv